Chembio enters wider US market with CLIA waiver for HIV barrel test
This article was originally published in Clinica
Granting the company wider access to the US market, Chembio Diagnostics has received CLIA waiver status for its rapid HIV Barrel test. Potentially an additional 189,000 testing sites across the US can now use the test.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.